Applied Biosystems and BioTrove to Collaborate on Integrated Platform for High Throughput Genotyping
News Nov 13, 2007
Applied Biosystems will develop and market custom-built arrays of TaqMan® SNP Genotyping Assays pre-loaded on BioTrove’s OpenArray™ platform. This platform will integrate the ease-of-use and reproducibility of Applied Biosystems’ TaqMan SNP Genotyping Assays with BioTrove’s flexible high density assay format, enabling researchers to perform high throughput genotyping studies at a lower total cost.
Under the terms of the agreement, Applied Biosystems retains the rights to commercialize all genotyping applications, including assays other than ones based on TaqMan technology, for BioTrove’s platform.
Applied Biosystems plans to commercialize and service all components of this analysis platform during the second half of 2008. Applied Biosystems is also retaining an option to collaborate with BioTrove, Inc. for developing and commercializing the OpenArray platform for high throughput gene expression applications.
In a separate agreement, Applied Biosystems has granted a worldwide license under patent rights related to real-time thermal cyclers, microfluidics, and data analysis to BioTrove, Inc.
Under the agreement, BioTrove will have the right to manufacture and sell real-time thermal cyclers and array sample loaders in the life sciences research field, as well as to develop further real-time PCR applications for its OpenArray platform. Financial terms of the agreements were not disclosed.
Overall, this collaboration is expected to expand the potential uses of TaqMan technology across a wide range of genomic applications.
When pre-loaded with TaqMan SNP Genotyping Assays, BioTrove’s OpenArray platform enables researchers to perform genotyping studies that investigate tens to hundreds of single base changes, or SNPs (single nucleotide polymorphisms) across hundreds to thousands of samples. This scale of genotyping study is often performed as part of breeding and quality control processes in the agricultural industry.
Researchers using this integrated platform can experience an end-to-end genotyping workflow of less than four hours, enabling them to analyze thousands of samples in days in contrast to weeks on alternative genotyping platforms.
The razor-thin BioTrove OpenArray consumable device has a flexible array format that enables researchers to perform more than 3,000 different high throughput genotyping assays in a variety of different configurations.
The OpenArray platform will provide researchers with customized arrays of TaqMan SNP Genotyping Assays from a single source, simplifying their workflow for performing a variety of high throughput genotyping applications.
As genome editing technologies advance toward clinical therapies, they are raising hopes of a completely new way to treat disease. However, challenges need to be addressed before potential treatments can be widely used in patients. To tackle these challenges, the National Institutes of Health has launched the Somatic Cell Genome Editing program, which has awarded multiple grants including more than $3.6 million to assess the safety of genome editing in human cells and tissues.